Design of New Drugs for the Treatment of Alzheimer’s Disease Based on Tacrine Structure

Author(s): Roney A.N. de Aquino, Luzia V. Modolo, Rosemeire B. Alves, Angelo de Fatima

Journal Name: Current Drug Targets

Volume 14 , Issue 3 , 2013

Become EABM
Become Reviewer
Call for Editor


Tacrine was the first drug approved by FDA for the treatment of Alzheimer’s disease. However, its use was restricted in function of side effects observed in some patients. Investigations on the structural basis by which tacrine inhibits cholinesterases activity brought new perspectives for the design of more potent analogs with fewer side effects. This review discusses the recent advances on the development of tacrine-structure-based compounds capable to target multiple molecules involved in Alzheimer’s disease. Detailed information on strategies of molecular modifications commonly used in medicinal chemistry, such as bioisosterism, hybridization, dimerization and simplification is presented as well.

Keywords: Alzheimer's disease, tacrine, bioisosterism, dimerization, hybridization, molecular simplification, multi target directed ligands

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2013
Page: [378 - 397]
Pages: 20
DOI: 10.2174/1389450111314030010
Price: $65

Article Metrics

PDF: 11